Pharmacokinetics of diclofenac after oral administration of its potassium salt in sachet and tablet formulations

Arzneimittel-Forschung/Drug Research

Volumn 50, Issue 1, 2000, Pages 43-47

  Marzo, Antonio ^a,b   Dal Bo, Lorenzo ^a   Verga, Filippo ^a   Ceppi Monti, Nunzia ^a   Abbondati, Guido ^a   Aleotti Tettamanti, Rosella ^a   Crivelli, Fabrizio ^a   Richard Uhr, Mario ^a   Ismaili, Shevqet ^a  

^a IPAS SA   (Switzerland)

^b IPASSA Inst for P/A S   (Switzerland)

Author keywords

CAS 15307 86 5; Cataflam ; Diclofenac potassium salt, absorption rate, bioavailability, plasma concentrations, sachet formulation; Voltfast

Indexed keywords

DICLOFENAC; DICLOFENAC POTASSIUM; UNCLASSIFIED DRUG;

ADULT; ANALGESIA; AREA UNDER THE CURVE; ARTICLE; CALCULATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG FORMULATION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE;

EID: 0033984733     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1300162     Document Type: Article

References (13)

1. [1] Martindale - The Extra Pharmacopoeia 31st Ed., pp. 36-37, The Royal Pharmaceutical Society, London (1996)
2. [2] Todd, P. A., Sorkin, E. M., Diclofenac sodium: a reappraisal of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy. Drugs 35, 244 (1988)
3. [3] Zanini, G. M., Swiss regulations for controlling clinical trials. Pharmacol. Res. 37, 321 (1998)
4. [4] Shah, V. P., Midha, K. K., Dighe, S. et al., Analytical methods validation: bioavailability, bioequivalence and pharmacokinetic studies. J. Pharm. Sci. 81, 309 (1992)
5. [5] Marzo, A., Pharmacokinetic analysis, bioavailability and operating guidelines. J. Pharm. Pharmacol. 49, 1259 (1997)
6. [6] Marzo, A., Ceppi Monti, N., Acceptable and unacceptable procedures in bioavailability and bioequivalence trials. Pharmacol. Res. 38, 401 (1998)
7. [7] Anonymous, CPMP. Note for guidance on the investigation of bioavailability and bioequivalence. CPMP / EWP / QWP / 1401 /98 draft. December 1998
8. [8] Anonymous. In vivo Bioequivalence Guidances / General Information. United States Pharmacopoeia 23 (Suppl. 8), 4382 (1998)
9. [9] Schuirmann, D. J., A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J. Pharmacokinet. Biopharm. 15, 657 (1987)
10. [10] Riess, W., Stierlin, H., Degen, P. et al., Pharmacokinetics and metabolism of the anti-inflammatory agent voltaren. Scand. J. Rheumatol. Suppl. 22, 17 (1978)
11. [11] Derendorf, H., Mullersman, G., Bart, J. et al., Pharmacokinetics of diclofenac sodium after intramuscular administration in combination with triamcinolone acetate. Eur. J. Clin. Pharmacol. 31, 263 (1986)
12. [12] Davies, N. M., Anderson, K. E., Clinical pharmacokinetic of diclofenac. Therapeutic insights and pitfalls. Clin. Pharmacokinet. 33, 184 (1997)
13. [13] McNeely, W., Goa, K. L., Diclofenac-potassium in migraine. A review. Drugs 57, 991 (1999)